Elicio Therapeutics, Inc. (ELTX) analyst actions
Rating and price-target actions on ELTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ELTX overview →
4 measured ELTX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma | Press release | +1.88% | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Reach Out | Press release | -0.29% | +2.35% | |
| Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX) | Press release | -3.01% | +49.29% | |
| Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma | Press release | -1.33% | -3.73% |
Keep exploring
More ELTX: earnings → · SEC filings → · ELTX overview →